<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929980</url>
  </required_header>
  <id_info>
    <org_study_id>2012:1089</org_study_id>
    <nct_id>NCT01929980</nct_id>
  </id_info>
  <brief_title>Bortezomib to Treat Significant Complication of HSCT</brief_title>
  <acronym>Bortezomib</acronym>
  <official_title>Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the safety and effectiveness of a drug called
      Bortezomib for the treatment of low blood cell counts after bone marrow transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to study the safety and effectiveness of a drug called
      bortezomib for the treatment of autoimmune cytopenia(s) (low blood cell counts) after bone
      marrow transplant that are not responding to standard treatments. Autoimmune cytopenias are
      low blood counts due to antibodies or proteins produced against an individual's own blood
      cells. Having a low red blood cell count (anemia) can make a person feel tired and require
      blood transfusions frequently. A low platelet count (blood cells that help blood to clot) can
      make a person bleed or bruise easily. A low neutrophil (white blood cell) count can make a
      person have infections.

      All of these things can be a serious complication after bone marrow transplant and can cause
      prolonged hospital stay. Bortezomib is being used in children with certain types of blood
      cancer, however, bortezomib has not been used in children with autoimmune cytopenia(s) and
      its use in this study is investigational.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response</measure>
    <time_frame>6 weeks</time_frame>
    <description>For Autoimmune Hemolytic Anemia- At least 3 of 5 criteria should be met.
Stabilization of hemoglobin without transfusions by 2 weeks
Conversion of DAT from + to - by 6 weeks
Normalization of serum haptoglobin levels by 6 weeks
Normalization of indirect bilirubin levels by 6 weeks
Reduction in the frequency of transfusions by 50% by 4 weeks
For Autoimmune Neutropenia- At least 2 of 3 criteria should be met.
Stabilization of absolute neutrophil count by 2 weeks
Undetectable antineutrophil antibodies by 6 weeks
Reduction in GCSF dose by 50% by 6 weeks
For Autoimmune Thrombocytopenia- At least 2 of 3 criteria should be met.
Stabilization of platelet count without platelet transfusions by 2 weeks
Undetectable antiplatelet antibodies by 6 weeks
Reduction in the frequency of platelet transfusions by 50% from pre-bortezomib values by 6 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <condition>Refractory Autoimmune Cytopenia(s)</condition>
  <arm_group>
    <arm_group_label>Bortezomib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.
The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>Bortezomib</arm_group_label>
    <other_name>PS-341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients, having undergone allogeneic stem cell transplantation at our center.

          -  Should have failed at least 2 standard treatments for autoimmune cytopenias. Standard
             treatments include corticosteroids, rituximab, IVIG, plasmapheresis, withdrawal of
             cyclosporine, cyclophosphamide and MMF. Definition of &quot;failed&quot; treatment will be no
             response of cytopenia after 2 weeks of continued treatment OR requirement of daily
             GCSF at 10 mcgs/kg/day for autoimmune neutropenia despite 2 weeks of treatment,
             transfusions of packed red blood cells or platelets 3 times weekly for 2weeks despite
             continued treatment OR 5days/week plasmapheresis for 2 weeks and inability to wean the
             duration.

          -  Definition of autoimmune hemolytic anemia- development of anemia, where there is a
             hemoglobin drop of &gt;2 g/dL/48 hours or an absolute value of hemoglobin &lt; 8 g/dL, and
             evidence of hemolysis by positive direct Coombs test with compatible peripheral blood
             cell morphology, reticulocyte count and bilirubin level.

          -  Definition of autoimmune neutropenia - absolute neutrophil counts &lt; 500 for 2 weeks
             and presence of anti-neutrophil antibodies.

          -  Definition of autoimmune thrombocytopenia- Platelet counts &lt; 20,000 cells/uL for 2
             weeks and presence of anti-platelet antibodies.

        Exclusion Criteria:

          -  Ongoing life threatening infections

          -  Documented anaphylaxis to bortezomib

          -  Failed engraftment

          -  Relapse of primary malignancy

          -  â‰¥6/8 matched or haploidentical transplants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Filipovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <results_first_submitted>October 18, 2016</results_first_submitted>
  <results_first_submitted_qc>October 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2016</results_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSCT</keyword>
  <keyword>cytopenia</keyword>
  <keyword>immune suppression</keyword>
  <keyword>proteasome inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bortezomib</title>
          <description>Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.
The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11
Bortezomib</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bortezomib</title>
          <description>Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.
The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11
Bortezomib</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response</title>
        <description>For Autoimmune Hemolytic Anemia- At least 3 of 5 criteria should be met.
Stabilization of hemoglobin without transfusions by 2 weeks
Conversion of DAT from + to - by 6 weeks
Normalization of serum haptoglobin levels by 6 weeks
Normalization of indirect bilirubin levels by 6 weeks
Reduction in the frequency of transfusions by 50% by 4 weeks
For Autoimmune Neutropenia- At least 2 of 3 criteria should be met.
Stabilization of absolute neutrophil count by 2 weeks
Undetectable antineutrophil antibodies by 6 weeks
Reduction in GCSF dose by 50% by 6 weeks
For Autoimmune Thrombocytopenia- At least 2 of 3 criteria should be met.
Stabilization of platelet count without platelet transfusions by 2 weeks
Undetectable antiplatelet antibodies by 6 weeks
Reduction in the frequency of platelet transfusions by 50% from pre-bortezomib values by 6 weeks</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bortezomib</title>
            <description>Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.
The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11
Bortezomib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response</title>
          <description>For Autoimmune Hemolytic Anemia- At least 3 of 5 criteria should be met.
Stabilization of hemoglobin without transfusions by 2 weeks
Conversion of DAT from + to - by 6 weeks
Normalization of serum haptoglobin levels by 6 weeks
Normalization of indirect bilirubin levels by 6 weeks
Reduction in the frequency of transfusions by 50% by 4 weeks
For Autoimmune Neutropenia- At least 2 of 3 criteria should be met.
Stabilization of absolute neutrophil count by 2 weeks
Undetectable antineutrophil antibodies by 6 weeks
Reduction in GCSF dose by 50% by 6 weeks
For Autoimmune Thrombocytopenia- At least 2 of 3 criteria should be met.
Stabilization of platelet count without platelet transfusions by 2 weeks
Undetectable antiplatelet antibodies by 6 weeks
Reduction in the frequency of platelet transfusions by 50% from pre-bortezomib values by 6 weeks</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemolytic Anemia (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bortezomib</title>
          <description>Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.
The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11
Bortezomib</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumatosis Coli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>C diff colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Cellulitis at subcutaneous injection site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pooja Khandelwal, MD</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-803-9063</phone>
      <email>Pooja.Khandelwal@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

